After a courtship of more than six months, Shire won over the fellow drug maker Baxalta on Monday in a deal valued at about $31 billion. The combination would create a giant in the treatment of rare diseases.
Baxalta, which was spun out of Baxter International, generates a large portion of its sales from Advate, a drug for hemophilia. The company also has a portfolio of plasma therapies and treatments for immune diseases.
00:02 AT&T Aims for an Empire in Merger Talks With Time Warner4
21:31 Time Warner jumps after hours on report it could sell for $110 per share to AT&T
12:55 McDonald's shares pop as investors cheer third-quarter beat
11:10 Merged BAT-Reynolds could be loaded with up to $55 billion of debt, analysts say5